- Regeneron (REGN, Financial) and Sanofi presented positive Phase 4 trial results for Dupixent® in treating atopic dermatitis in patients with skin of color.
- 76% of participants achieved a ≥75% improvement in disease severity, with notable reduction in itch and hyperpigmentation.
- Safety profile consistent with prior studies, with 42% of participants reporting adverse events.
Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi have revealed encouraging outcomes from their Phase 4 DISCOVER trial for Dupixent® (dupilumab), focusing on patients with atopic dermatitis and skin of color. Held at the 2025 Revolutionizing Atopic Dermatitis (RAD) Conference, the study highlights significant advancements in addressing this underserved demographic.
Key statistics from the 120-patient trial—which included 82% Black participants—show that after 24 weeks, 76% attained a ≥75% improvement in disease severity (EASI-75). Additionally, 53% of participants experienced a meaningful reduction in itch, achieving a ≥4-point improvement on the peak-pruritus numerical rating scale. A notable 53% decrease in post-inflammatory hyperpigmentation was also observed.
The trial also highlighted substantial improvements in dry skin symptoms, with the percentage of patients reporting significant disturbance due to dry skin plummeting from 78% to 18%. These improvements were noticeable as early as two weeks into the treatment for some patients. The safety profile was consistent with existing Dupixent data, with a 42% adverse event rate, including common side effects such as headache (3%), conjunctivitis (3%), and upper respiratory tract infections (2%).
These findings reinforce Dupixent's efficacy and broaden its clinical value in treating atopic dermatitis in a diverse population, addressing fundamental health equity concerns in dermatology.
